234 related articles for article (PubMed ID: 35579781)
1. Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study.
Chen G; Li X; Cui Q; Zhou Y; Zhao B; Mei D; Xuemei
Int Urol Nephrol; 2022 Nov; 54(11):2949-2957. PubMed ID: 35579781
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose cotransporter-2 inhibitors and cardiovascular safety profile: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system.
Zhang L; Pan C; Yang X; Jiang D; Cao M
Expert Opin Drug Saf; 2024 Jun; 23(6):785-792. PubMed ID: 37203199
[TBL] [Abstract][Full Text] [Related]
3. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.
Rampersad C; Kraut E; Whitlock RH; Komenda P; Woo V; Rigatto C; Tangri N
Am J Kidney Dis; 2020 Oct; 76(4):471-479.e1. PubMed ID: 32464161
[TBL] [Abstract][Full Text] [Related]
4. Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System.
Hu Y; Bai Z; Tang Y; Liu R; Zhao B; Gong J; Mei D
J Diabetes Res; 2020; 2020():3695101. PubMed ID: 32695827
[TBL] [Abstract][Full Text] [Related]
5. The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study.
Goldman A; Fishman B; Twig G; Raschi E; Cukierman-Yaffe T; Moshkovits Y; Pomerantz A; Ben-Zvi I; Dankner R; Maor E
Cardiovasc Diabetol; 2023 Jan; 22(1):16. PubMed ID: 36694178
[TBL] [Abstract][Full Text] [Related]
6. Clinical Spectrum and Mechanism of Acute Kidney Injury in Patients with Diabetes Mellitus on SGLT-2 Inhibitors.
Perlman A; Heyman SN; Stokar J; Darmon D; Muszkat M; Szalat A
Isr Med Assoc J; 2018 Aug; 20(8):513-516. PubMed ID: 30084579
[TBL] [Abstract][Full Text] [Related]
7. Acute kidney injury following the use of different proton pump inhibitor regimens: A real-world analysis of post-marketing surveillance data.
Chen G; Ning LJ; Qin Y; Zhao B; Mei D; Li XM
J Gastroenterol Hepatol; 2021 Jan; 36(1):156-162. PubMed ID: 32542684
[TBL] [Abstract][Full Text] [Related]
8. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database.
Perlman A; Heyman SN; Matok I; Stokar J; Muszkat M; Szalat A
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1108-1113. PubMed ID: 29174031
[TBL] [Abstract][Full Text] [Related]
9. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
Orogun L; Chyou TY; Nishtala PS
Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
[TBL] [Abstract][Full Text] [Related]
10. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis.
Menne J; Dumann E; Haller H; Schmidt BMW
PLoS Med; 2019 Dec; 16(12):e1002983. PubMed ID: 31815931
[TBL] [Abstract][Full Text] [Related]
11. Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real-world pharmacoepidemiology study of post-marketing surveillance data.
Chen G; Qin Y; Fan QQ; Zhao B; Mei D; Li XM
Cancer Med; 2020 Sep; 9(18):6576-6585. PubMed ID: 32720449
[TBL] [Abstract][Full Text] [Related]
12. Identification of risk factors associated with acute kidney injury in patients taking sodium-glucose cotransporter-2 inhibitors.
Schumacher C; Chorpash A; Bolch C; Eagan K; Nimer S; Van Dril E
Pharmacotherapy; 2024 Mar; 44(3):249-257. PubMed ID: 38131129
[TBL] [Abstract][Full Text] [Related]
13. Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors.
Alkabbani W; Gamble JM
Br J Clin Pharmacol; 2023 Feb; 89(2):431-439. PubMed ID: 34964156
[TBL] [Abstract][Full Text] [Related]
14. A cohort study of sodium-glucose cotransporter-2 inhibitors after acute kidney injury among Veterans with diabetic kidney disease.
Murphy DP; Wolfson J; Reule S; Johansen KL; Ishani A; Drawz PE
Kidney Int; 2024 Jul; 106(1):126-135. PubMed ID: 38685561
[TBL] [Abstract][Full Text] [Related]
15. Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data.
Dong S; Sun C
Front Endocrinol (Lausanne); 2022; 13():1032199. PubMed ID: 36583004
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin receptor-neprilysin inhibitor and sodium-dependent glucose cotransporter-2 inhibitor-associated renal injury: a pharmacovigilance study.
Chen C; Wu B; Zhang C; Xu T
Expert Opin Drug Saf; 2023 Mar; 22(3):259-266. PubMed ID: 36044355
[TBL] [Abstract][Full Text] [Related]
17. Correlations Between SGLT-2 Inhibitors and Acute Renal Failure by Signal Detection Using FAERS: Stratified Analysis for Reporting Country and Concomitant Drugs.
Katsuhara Y; Ikeda S
Clin Drug Investig; 2021 Mar; 41(3):235-243. PubMed ID: 33564981
[TBL] [Abstract][Full Text] [Related]
18. Do sodium-glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real-world study.
Zhao B; Shen J; Zhao J; Pan H
J Diabetes Investig; 2021 Aug; 12(8):1400-1407. PubMed ID: 33325646
[TBL] [Abstract][Full Text] [Related]
19. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system.
Fan Q; Ma J; Zhang B; Li Q; Liu F; Zhao B
Cancer Chemother Pharmacol; 2020 Nov; 86(5):655-662. PubMed ID: 33001273
[TBL] [Abstract][Full Text] [Related]
20. Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis.
Nadkarni GN; Ferrandino R; Chang A; Surapaneni A; Chauhan K; Poojary P; Saha A; Ferket B; Grams ME; Coca SG
Diabetes Care; 2017 Nov; 40(11):1479-1485. PubMed ID: 28827404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
